for Journals by Title or ISSN
for Articles by Keywords
Followed Journals
Journal you Follow: 0
Sign Up to follow journals, search in your chosen journals and, optionally, receive Email Alerts when new issues of your Followed Journals are published.
Already have an account? Sign In to see the journals you follow.
Journal Cover The Medical Letter
  [SJR: 0.142]   [H-I: 16]   [5 followers]  Follow
   Full-text available via subscription Subscription journal
   ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
   Published by The Medical Letter, Inc Homepage  [1 journal]
  • Addendum: Timing of Levothyroxine
    • Authors: admin
      Abstract: Date:  February 1, 2016 Issue #:  1487 Summary:  In our October 26, 2015 article on drugs for hypothyroidism (Med Lett Drugs Ther 2015; 57:147), we said that levothyroxine should be taken on an empty stomach with a full glass of water 30-60 minutes (60 is preferable) before breakfast. We should have added that taking the drug consistently at bedtime, at least 3 hours after the last meal, is an alternative that some patients may find more convenient.
      PubDate: Mon, 25 Jan 2016 20:14:39 +000
  • Drugs for Rosacea
    • Authors: admin
      Abstract: Date:  February 1, 2016 Issue #:  1487 Summary:  This common, chronic inflammatory facial eruption of unknown cause is more prevalent in women than in men. Rosacea is characterized by erythema and telangiectasia, and sometimes by recurrent, progressive crops of acneiform papules and pustules, usually on the central part of the face. Some patients develop granulomas and tissue hypertrophy, which may lead to rhinophyma (a bulbous nose), particularly in men. Blepharitis and conjunctivitis are common. Keratitis and corneal scarring occur rarely.
      PubDate: Mon, 25 Jan 2016 18:10:43 +000
  • Rolapitant (Varubi) for Prevention of Delayed Chemotherapy-Induced Nausea
           and Vomiting
    • Authors: admin
      Abstract: Date:  February 1, 2016 Issue #:  1487 Summary:  The FDA has approved rolapitant (Varubi – Tesaro), an oral substance P/neurokinin 1 (NK1) receptor antagonist, for use with other antiemetics to prevent delayed nausea and vomiting associated with cancer chemotherapy in adults. It is the third substance P/NK1 receptor antagonist to be approved in the US; aprepitant (Emend) and netupitant (only available in combination with the 5-HT3 receptor antagonist palonosetron as Akynzeo) were approved earlier for prevention of both acute and delayed chemotherapy-induced nausea and vomiting.
      PubDate: Wed, 13 Jan 2016 12:47:18 +000
  • Drugs for Acne
    • Authors: admin
      Abstract: Date:  February 1, 2016 Issue #:  1487 Summary:  The pathogenesis of acne is multifactorial: follicular hyperkeratinization, bacteria, sebum production, androgens, and inflammation all play a role. The gram-positive microaerophilic bacteria Propionibacterium acnes promotes development of acne lesions by secreting chemotactic factors that attract leukocytes to the follicle, causing inflammation.
      PubDate: Wed, 13 Jan 2016 12:46:40 +000
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2015